Atara Biotherapeutics, Inc. Contracts & Agreements

Amendment No. 9 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated April 30, 2024 (Filed With SEC on August 12, 2024)

Amendment No. 10 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated May 31, 2024 (Filed With SEC on August 12, 2024)

Transition, Separation and Consulting Agreement, dated August 12, 2024, by and between Pascal Touchon and Atara Biotherapeutics, Inc (Filed With SEC on August 12, 2024)

Executive Employment Agreement, dated August 12, 2024, by and between AnhCo Nguyen and Atara Biotherapeutics, Inc (Filed With SEC on August 12, 2024)

Amendment No. 8 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated March 31, 2024 (Filed With SEC on May 9, 2024)

Amendment No. 6 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated December 30, 2023 (Filed With SEC on March 28, 2024)

Amendment No. 7 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated January 31, 2024 (Filed With SEC on March 28, 2024)

Amended and Restated Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament dated October 31, 2023 (Filed With SEC on March 28, 2024)

Form of Warrant (Filed With SEC on January 9, 2024)

Form of Securities Purchase Agreement (Filed With SEC on January 9, 2024)

Amendment No. 5 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated September 27, 2023 (Filed With SEC on November 1, 2023)

Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice (Filed With SEC on November 1, 2023)

Sales Agreement, dated November 1, 2023, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on November 1, 2023)

Purchase and Sale Agreement between Atara Biotherapeutics, Inc., and HCR Molag Fund, L.P., dated December 20, 2023 (Filed With SEC on February 8, 2023)

Amendment No. 3 to Commercial Manufacturing Services Agreement dated as of August 1, 2022 by and between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc (Filed With SEC on November 8, 2022)

Termination, Amendment and Program Transfer Agreement dated August 2, 2022, by and between Atara Biotherapeutics, Inc., and Bayer AG (Filed With SEC on November 8, 2022)

Amendment No. 1 to the Commercialization Agreement dated September 28, 2022, by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament (Filed With SEC on November 8, 2022)

Amendment No. 2 to Commercial Manufacturing Services Agreement dated as of May 31, 2022 by and between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc (Filed With SEC on August 8, 2022)

Asset Purchase Agreement, dated as of January 26, 2022, by and between Atara Biotherapeutics, Inc., FUJIFILM Diosynth Biotechnologies California, Inc., and for certain limited... (Filed With SEC on April 4, 2022)

Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament, dated October 2, 2021 (Filed With SEC on February 28, 2022)

Second Amendment to Lease, by and between Atara Biotherapeutics, Inc. and 611 Gateway Center LP, LLC, dated December 9, 2021 (Filed With SEC on February 28, 2022)

Fourth Amended and Restated Research and Development Collaboration Agreement between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research,... (Filed With SEC on February 28, 2022)

Fourth Amended and Restated Exclusive License Agreement between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated December 17, 2021 (Filed With SEC on February 28, 2022)

Form of Atara Biotherapeutics, Inc. Executive Employment Agreement (Filed With SEC on February 28, 2022)

Sales Agreement, dated November 26, 2021, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on November 26, 2021)

Amendment No. 1 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc., and Cognate BioServices Inc., dated September 1, 2021 (Filed With SEC on November 4, 2021)

Deed of Amendment Number 1 to Third Amended and Restated License Agreement dated April 21, 2021 (Filed With SEC on August 9, 2021)

Research, Development and License Agreement, by and between Atara Biotherapeutics, Inc. and Bayer AG, dated December 4, 2020 (Filed With SEC on March 1, 2021)

Underwriting Agreement, dated as of December 8, 2020, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Evercore Group L.L.C. and Mizuho Securities USA LLC (Filed With SEC on December 9, 2020)

Form of Pre-Funded Warrant (Filed With SEC on December 9, 2020)

Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August... (Filed With SEC on November 9, 2020)

Third Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical... (Filed With SEC on November 9, 2020)

Amended and Restated 2018 Inducement Plan (Filed With SEC on November 9, 2020)

First Amendment to Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated as of October 21, 2020 (Filed With SEC on November 9, 2020)

Underwriting Agreement, dated as of May 26, 2020, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Cowen and Company, LLC and Evercore Group L.L.C (Filed With SEC on May 28, 2020)

Form of Pre-Funded Warrant (Filed With SEC on May 28, 2020)

Sales Agreement, dated February 27, 2020, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on February 27, 2020)

Description of Securities (Filed With SEC on February 27, 2020)

Amendment No. 4 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 4, 2019 (Filed With SEC on February 27, 2020)

Amendment No. 5 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 27, 2019 (Filed With SEC on February 27, 2020)

Commercial Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated December 24, 2019 (Filed With SEC on February 27, 2020)

Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on November 7, 2019)

Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2018 Inducement Plan (Filed With SEC on November 7, 2019)

Second Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical... (Filed With SEC on November 7, 2019)

Second Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August... (Filed With SEC on November 7, 2019)

Amended and Restated Amendment No. 2 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated... (Filed With SEC on November 7, 2019)

Amendment No. 3 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated June 28, 2019 (Filed With SEC on November 7, 2019)

Form of Executive Employment Agreement (Filed With SEC on August 8, 2019)

Underwriting Agreement, dated as of July 18, 2019, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Cowen and Company, LLC (Filed With SEC on July 22, 2019)

Form of Pre-Funded Warrant (Filed With SEC on July 22, 2019)

Executive Employment Agreement, dated May 23, 2019, by and between Pascal Touchon and Atara Biotherapeutics, Inc (Filed With SEC on May 28, 2019)

Sales Agreement, dated February 26, 2019, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on February 26, 2019)

Amendment No. 1 to the Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated as of August 30, 2018 (Filed With SEC on February 26, 2019)

Transition and Separation Agreement, dated January 2, 2019, by and between Isaac Ciechanover and Atara Biotherapeutics, Inc (Filed With SEC on January 3, 2019)

Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Council of the Queensland Institute of Medical Research, dated September 23,... (Filed With SEC on August 1, 2018)

Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Council of the Queensland Institute of Medical Research,... (Filed With SEC on August 1, 2018)

Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate Bioservices, Inc., dated August 2015, as amended (Filed With SEC on August 1, 2018)

Form of Employment Agreement by and between Atara Biotherapeutics, Inc. and its executive officers (Filed With SEC on August 1, 2018)

Atara Biotherapeutics, Inc. 2018 Inducement Plan (the Inducement Plan) (Filed With SEC on May 8, 2018)

Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the Inducement Plan (Filed With SEC on May 8, 2018)

Form of Stock Option Agreement and Stock Option Grant Notice under the Inducement Plan (Filed With SEC on May 8, 2018)

Underwriting Agreement, dated as of February 28, 2018, by and among Atara Biotherapeutics, Inc., J.P. Morgan Securities LLC and Cowen and Company, LLC (Filed With SEC on March 2, 2018)

Underwriting Agreement, dated as of January 3, 2018, by and among Atara Biotherapeutics, Inc., J.P. Morgan Securities LLC and Cowen and Company, LLC (Filed With SEC on January 4, 2018)

Executive Employment Agreement between Atara Biotherapeutics, Inc. and Joe Newell, dated March 20, 2017 (Filed With SEC on August 7, 2017)

Executive Employment Agreement between Atara Biotherapeutics, Inc. and Derrell Porter, M.D., dated March 23, 2017 (Filed With SEC on August 7, 2017)

Forms of Inducement Grant Notice and Inducement Grant Agreement (Filed With SEC on August 7, 2017)

ATARA BIOTHERAPEUTICS, INC. $75,000,000 COMMONSTOCK SALES AGREEMENT (Filed With SEC on March 27, 2017)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for GAD SOFFER (Filed With SEC on March 9, 2017)

CONSENT TO SUBLEASE (Filed With SEC on August 8, 2016)

ATARA BIOTHERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN First Amended and Restated: May 28, 2014 Second Amended and Restated: __________, 2016 Approved by the Stockholders:... (Filed With SEC on August 8, 2016)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for HEATHER D. TURNER (Filed With SEC on May 6, 2016)

OFFICE LEASE 611 GATEWAY BOULEVARD BP GATEWAY CENTER LLC, a Delaware limited liability company as Landlord, and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation , as Tenant. (Filed With SEC on March 4, 2016)

4360 Park Terrace Drive WESTLAKE VILLAGE, CALIFORNIA 91361 (Filed With SEC on November 6, 2015)

FIRST AMENDMENT TO LEASE (Filed With SEC on November 6, 2015)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for ISAAC CIECHANOVER, M.D. (Filed With SEC on October 16, 2015)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for JOHN F. MCGRATH, JR. (Filed With SEC on October 16, 2015)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for CHRISTOPHER M. HAQQ, M.D., PH.D. (Filed With SEC on October 16, 2015)

ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for MITCHALL CLARK (Filed With SEC on October 16, 2015)

AMENDMENT NUMBER ONE TO THE EXCLUSIVE OPTION AGREEMENT (Filed With SEC on August 7, 2015)

Atara Biotherapeutics, Inc. Common Stock Underwriting Agreement (Filed With SEC on July 7, 2015)

REVISED (Filed With SEC on July 7, 2015)

EXCLUSIVE LICENSE AGREEMENT for MSKs technology EBV/CMV and WT1 specific T-cells TABLE OF CONTENTS (Filed With SEC on June 29, 2015)

EXCLUSIVE OPTION AGREEMENT for MSKs technology EBV/CMV and WT1 specific T-cells (Filed With SEC on May 11, 2015)

Atara Biotherapeutics, Inc. Common Stock Underwriting Agreement (Filed With SEC on February 9, 2015)

SUBLEASEAGREEMENT (Filed With SEC on September 26, 2014)

Atara Biotherapeutics, Inc. Common Stock Underwriting Agreement (Filed With SEC on July 10, 2014)

ATARA BIOTHERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: MARCH 31, 2014 AMENDED AND RESTATED BY THE BOARD:MAY 28, 2014 APPROVED BY THE STOCKHOLDERS:JUNE 2,... (Filed With SEC on July 10, 2014)

ATARA BIOTHERAPEUTICS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on July 10, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and NINABIOSCIENCES, INC. Dated as of September 7, 2012 (Filed With SEC on July 10, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012 (Filed With SEC on July 10, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012 TABLE OF CONTENTS (Filed With SEC on July 10, 2014)

ATARA BIOTHERAPEUTICS, INC. INVESTORS RIGHTS AGREEMENT March 31, 2014 TABLE OF CONTENTS (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: MARCH 31, 2014 AMENDED AND RESTATED BY THE BOARD:MAY 28, 2014 APPROVED BY THE STOCKHOLDERS:JUNE 2,... (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on June 20, 2014)

NINA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF NOVEMBER 26, 2012 NINA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF NOVEMBER 26, 2012 (Filed With SEC on June 20, 2014)

PINTA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF NOVEMBER 26, 2012 PINTA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF NOVEMBER 26, 2012 (Filed With SEC on June 20, 2014)

SANTA MARIA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF NOVEMBER 26, 2012 SANTA MARIA BIOTHERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN EFFECTIVE AS OF... (Filed With SEC on June 20, 2014)

2012 EQUITY INCENTIVE PLAN STOCK UNIT AGREEMENT (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on June 20, 2014)

ATARA BIOTHERAPEUTICS, INC. EMPLOYMENT AGREEMENT (Filed With SEC on June 20, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and NINABIOSCIENCES, INC. Dated as of September 7, 2012 (Filed With SEC on June 20, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012 (Filed With SEC on June 20, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

EXCLUSIVE LICENSE AGREEMENT by and between AMGENINC. and SANTA MARIA BIOSCIENCES, INC. Dated as of September 7, 2012 TABLE OF CONTENTS (Filed With SEC on June 20, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

OFFICELEASE BASIC LEASEINFORMATION (Filed With SEC on June 20, 2014)

SUBLEASE AGREEMENT (Filed With SEC on June 20, 2014)

CONSENT TO SUBLEASE (Filed With SEC on June 20, 2014)

Category

Industry

Companies

Contracts

Atara Biotherapeutics, Inc. Contracts & Agreements